SEC Form 4Coverage since Jun 15, 2026
$TBPH insider trading
Over the last 12 months, Theravance Biopharma insiders reported no purchases and 3 sales totaling $6.1M across SEC Form 4 filings. 33% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $6.1M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 33% pre-arranged plans
Side
Price · $TBPH · 12Mvia TradingView
Top insiders · 12m
Samaha Eli—2× · $5.9M
Farnum RhondaSVP, COMM & MEDICAL AFFAIRS1× · $218K
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Samaha Eli10% | ▼ Sale | 6,964 | $17.14 | $119K | -0.1% | 2 tranches · indirect |
| Jul 1, 2026 | Samaha Eli10% | ▼ Sale | 336,697 | $17.2 | $5.8M | -3.5% | 3 tranches · indirect |
| Jun 15, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS · O | ▼ Sale | 13,314 | $16.39 | $218K | -5.4% | plan · 3 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TBPH feed.